Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 18/20 | 0.51 |
| ▸ | HTR2B | P41595 | 18/20 | 0.51 |
| ▸ | HTR2A | P28223 | 9/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL337382 | 1.00 | HTR2C (0.51) | HTR2CHTR2BHTR2A | |
| SCHEMBL337591 | 1.00 | HTR2C (0.51) | HTR2CHTR2BHTR2A | |
| Hydrochloric Acid SCHEMBL14816152 | 0.98 | HTR2C (0.50) | HTR2CHTR2BHTR2A | |
| Hydrochloric Acid SCHEMBL23124413 | 0.98 | HTR2C (0.50) | HTR2CHTR2BHTR2A | |
| Hydrochloric Acid SCHEMBL9940935 | 0.98 | HTR2C (0.50) | HTR2CHTR2BHTR2A | |
| SCHEMBL981281 | 0.89 | HTR2C (0.45) | HTR2CHTR2BHTR2A | |
| SCHEMBL21209411 | 0.89 | HTR2C (0.45) | HTR2CHTR2BHTR2A | |
| SCHEMBL21193054 | 0.89 | HTR2C (0.45) | HTR2CHTR2BHTR2A | |
| SCHEMBL15799573 | 0.89 | HTR2C (0.49) | HTR2CHTR2BHTR2A | |
| Hydrochloric Acid SCHEMBL3760136 | 0.87 | HTR2C (0.44) | HTR2CHTR2BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4159739-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2023-04-05 | — | — | EP | claimed |
| US-20240299352-A1 | COMBINATION THERAPIES WITH SETD2 INHIBITORS | Epizyme, Inc. | 2024-09-12 | — | — | US | disclosed |
| US-20230416228-A1 | AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEWYORK | 2023-12-28 | — | — | US | disclosed |
| EP-4217355-A1 | AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 | Forkhead Biotherapeutics, inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20230133671-A1 | SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES | Epizyme, Inc. (US) | 2023-05-04 | — | — | US | disclosed |
| WO-2022066938-A1 | AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 | FORKHEAD BIOTHERAPEUTICS, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
| US-20210155629-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CONTINEUM THERAPEUTICS, INC. | 2021-05-27 | — | — | US | disclosed |
| EP-2098526-B1 | Nitrogen-containing bicyclic compounds active on chronic pain conditions | NEUROTUNE AG (CH) | 2014-01-15 | — | — | EP | disclosed |
| EP-1940845-B1 | NOVEL AZETIDINE COMPOUNDS USEFUL IN THE TREATMENT OF FUNCTIONAL GASTROINTESTINAL DISORDERS, IBS AND FUNCTIONAL DYSPEPSIA | ALBIREO AB (SE) | 2013-06-12 | — | — | EP | disclosed |
| US-8334286-B2 | Substituted pyrrolo[1,2-A] pyrazines, compositions containing these, processes of making these, and uses thereof | NEUROTUNE AG (CH) | 2012-12-18 | — | — | US | disclosed |
| WO-2008090116-A1 | NOVEL PHARMACEUTICAL COMPOSITIONS | GLAXO GROUP LIMITED (GB) | 2008-07-31 | — | — | WO | disclosed |
| EP-1666465-B1 | Composition comprising a tachykinin receptor antagonist and a selective serotonin reuptake inhibitor | GLAXO GROUP LTD (GB) | 2008-05-07 | — | — | EP | disclosed |
| WO-2008046882-A2 | COMPOSITION COMPRISING AN NK-1 RECEPTOR ANTAGONIST AND AN SSRI FOR THE TREATMENT OF TINNITUS AND HEARING LOSS | GLAXO GROUP LIMITED (GB) | 2008-04-24 | — | — | WO | disclosed |
| US-20070270400-A1 | New compounds 303 | ALBIREO AB (SE) | 2007-11-22 | — | — | US | disclosed |
| US-20070099914-A1 | Piperidine Derivatives | NERRE THERAPEUTICS LIMITED (GB) | 2007-05-03 | — | — | US | disclosed |
| US-7189713-B2 | Piperidine derivatives | GLAXO GROUP LIMITED (GB) | 2007-03-13 | — | — | US | disclosed |
| US-7189713-B2 | Piperidine derivatives | GLAXO GROUP LIMITED (GB) | 2007-03-13 | — | — | US | disclosed |
| EP-1666465-A1 | Composition comprising a tachykinin receptor antagonist and a selective serotonin reuptake inhibitor | GLAXO GROUP LIMITED (GB) | 2006-06-07 | — | — | EP | disclosed |
| EP-1472256-B1 | PIPERIDINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2005-11-02 | — | — | EP | disclosed |
| US-20050176715-A1 | Piperidine derivatives | NERRE THERAPEUTICS LIMITED (GB) | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416228-A1 | AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 | FOXO1, FOXO3, GCKR | HTR2C 4542/4885HTR2B 4500/4885HTR2A 4025/4885 |
| US-20210155629-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CHRM1, CHRM2, CHRM5 | HTR2C 142/4885HTR2B 150/4885HTR2A 117/4885 |
| US-20070099914-A1 | Piperidine Derivatives | PTGES2, NFKBIA, PTGS2 | HTR2C 1390/4885HTR2B 1064/4885HTR2A 1432/4885 |
| US-20070270400-A1 | New compounds 303 | CYP11B2, CYP11B1, SDHA | HTR2C 2610/4885HTR2B 2003/4885HTR2A 3418/4885 |
| US-20050176715-A1 | Piperidine derivatives | NPSR1, NPY5R, SSTR5 | HTR2C 339/4885HTR2B 295/4885HTR2A 392/4885 |
| US-20240299352-A1 | COMBINATION THERAPIES WITH SETD2 INHIBITORS | SETD2, CARM1, SETDB1 | HTR2C 3918/4885HTR2B 4250/4885HTR2A 3189/4885 |
| US-20230133671-A1 | SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES | EZH2, HDAC2, SETD2 | HTR2C 2280/4885HTR2B 3075/4885HTR2A 2197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.